BioSpace News Archive

Ovation Science Inc. is pleased to announce that its DermSafe® Hand Sanitizer Lotion is now available in select locations of Source For Sports, a Canadian sporting goods retailer with over 130 locations across Canada.

- FDA Grants Priority Review and Sets PDUFA Date of May 30, 2021 - - Application Being Evaluated Under FDA;s Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs -

Testing to inform national research to assess impact of COVID-19 on racial minorities and underserved communities across the country

Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) has obtained a positive decision confirming that the Swedish Tax Agency shares the Company’s assessment that the Company’s proposed distribution of the shares in OncoZenge qualifies as a Lex Asea distribution in accordance with chapter 42, section 16 of the Income Tax Act, whi

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the unveiling of its new C360™ cervical spine portfolio, including the commercial launch of the Anterior Cervical Plating (ACP) system

Spotlight Therapeutics, Inc., a biotechnology company developing non-viral gene editing therapeutics for direct in vivo editing of target genes, closed its Series A financing bringing the total raised to $30 million. The financing was led by GV, formerly Google Ventures, with participation from additional undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the company’s Phase 1 study evaluating NT-I7 (efineptakin alfa), a novel long-acting human IL-7, in adult patients with mild COVID-19. The company-sponsored trial is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the Nat

Founded by serial bioentrepreneur Robert Clarke, Ph.D., with Roger Heerman, MBA, and Frazer Morgan, the executive leadership has over sixty-five combined years of biopharma experience and significant expertise in respiratory drug development and commercialization Venture syndicate with deep experience investing in respiratory and inflammatory diseases includes co-leads 5AM Ventures and Atlas Venture, with participation from leading European investor

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib

PureTech management to share research and clinical strategies for leveraging leadership in the lymphatic system and related immunology with the potential to deliver highly differentiated medicines